Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies
Titel:
Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies
Auteur:
Yong, W.P. Goh, B.C. Soo, R.A. Toh, H.C. Ethirajulu, K. Wood, J. Novotny-Diermayr, V. Lee, S.C. Yeo, W.L. Chan, D. Lim, D. Seah, E. Lim, R. Zhu, J.